Oxford Vaccine Partner Plans Trials In India, Manufacturing Soon | Read
Trials for the coronavirus vaccine developed at the Oxford University will begin in India as soon as a license is procured, said the Indian firm partnering the researchers in the UK. The vaccine AZD1222 had a favourable response in the first phase of clinical trials. It did not prompt any serious side effects and elicited antibody and T-cell immune responses, according to trial results published in The Lancet medical journal.
